Deals channel feed – Endpoints News

Deals channel feed

Regeneron throws struggling CytomX a lifeline with $30M cancer bispecific deal

3 years ago

GSK's cell therapy retreat hits another partner as drugmaker exits Immatics collaboration

3 years ago

For $30M, Chinese biopharma Simcere picks up regional rights to Idorsia’s insomnia drug

3 years ago

Updated: Picking up the pieces after lead drug imploded, Rafael Holdings gives up on early R&D in favor of deals

3 years ago

Private investment firm snaps up Pfizer facility in Western Australia

3 years ago

Roche doubles down on Jnana's drug discovery platform, kicking off second deal with $50M cash — while biotech bags $107M

3 years ago

Indivior snaps up Narcan owner for $145M upfront, with an eye on next-gen nasal spray

3 years ago

Ionis partners up with Metagenomi on drug discovery pact, shelling out $80M upfront

3 years ago

Aiming at mainstream markets, radiopharmaceutical partners engineer $260M cash deal

3 years ago

Norwegian biotech concludes 'strategic' review with a reverse merger

3 years ago

Following secretive AbCellera pact, Moderna picks up another antibody discovery deal via Harbour BioMed

3 years ago

As an Amgen's PhIII cardio plan takes shape, Royalty Pharma snags a stake in future sales

3 years ago

Updated: After a tortured run with a weak PARP player and cash fast running out, Clovis signals likely bankruptcy, slashes 115 staffers

3 years ago

By the numbers: As the pandemic biotech boom fades, it's beginning to look a lot like 2019 — or before

3 years ago

In latest AI tie-up, Sanofi partners with Insilico for six new targets

3 years ago

Lonnie Moulder’s new biotech play grabs $118M, steering into PhIII and more deals

3 years ago

For $700M+, Viatris nabs two biotechs as eye disease emphasis comes into view

3 years ago

Bayer drops an Ionis-partnered drug after sinking $240M into its development

3 years ago

'Forward, faster' and 200 jobs lighter as fibrosis and kidney disease get cut, Galapagos CEO Stoffels once again spotlights deals

3 years ago

After pulling IPO plans, Artiva partners with Affimed to speed up NK cell therapy combo

3 years ago

In spinning out cancer pipeline, Alkermes cites Inflation Reduction Act's hypothetical incentives for biologics R&D

3 years ago

CSL stacks up $4.5B in chips — with a $200M ante — to wager on the next-gen mRNA wave

3 years ago

CFIUS review triggers delay on F-star's sale to Chinese player

3 years ago

Exelixis shells out $100M cash in a pair of deals, shooting for different takes on CD47, ADCs

3 years ago

First page Previous page 46 47 484950 51 52 Next page Last page